media – Page 491 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

FDA Approval for Cannabis Based Epidiolex Medicine Against Seizures

Epidiolex, also known as purified cannabidiol was approved to treat Lennox-Gastaut syndrome and Dravet syndrome specifically in patients aged 2 and older. Both these conditions start during childhood. Recurrent seizures pose a huge risk of death.
- Source: FiercePharma
- 568
- June 27, 2018
FDA Medical marijuana New Approvals
Biotech Crinetics Therapeutics Raises $86 million in IPO

The San Diego-based biotech company Crinetics Therapeutics recently raised $86 million in an IPO. Prior to the new funding, the company received $63.5 million in series B funding and will see its lead asset through phase 2.
- Source: FierceBiotech
- 797
- June 26, 2018
biotech Clinical Trials endocrine disorders
Indian Healthcare Startup SigTuple Raised $19 Million AI Based Products Development

India, Bengaluru based SigTuple, a startup focusing on Artificial Intelligence for Healthcare has raised $19 million in their series B funding. The investment was led by IDG Ventures, pi Ventures Partners along with Accel, Axilor Ventures, VH Capital, Endiya Partners and Flipkart’s executive chairman Binny Bansal. The startup has also bagged venture debt from Trifecta Capital in this round. In an earlier investment round, the company raised $6.5 million from various investors.
- Source: Analytics India
- 709
- June 26, 2018
AI Company Insight digital health start ups
Glaukos Corporation to receive Pre-Market approval for Next-Gen iStent

The inject is developed to achieve the natural outflow of aqueous humor by making two patent bypasses through the trabecular meshwork, glaucomatous eyes the main source of resistance resulting in multi-directional flow through Schlemm’s canal
- Source: BioSpectrumAsia
- 554
- June 26, 2018
FDA medtech New Approvals Optometry
What are the Impacts of Multiple Stents?

A shocking report revealed that patients with multiple stents or having longer stent greater than 31.5mm could be associated with high risk of mortality. Around 4.5% of patients died within a year of angioplasty. Death occurred in patients between the age group 35-75, where most of the people were elderly. Similarly, more patients who received metal stents had to be re-hospitalized, compared to those who received sophisticated drug-eluting stents.
- Source: India Times
- 996
- June 26, 2018
coronary stent medical device Researches
Overuse of Multivitamins could be Harmful

Usage of multivitamins either through prescription or on own accord possibly crossed a limit in the past few years. New research published in Journal of American College of Cardiology reveals that health supplements can increase the risk of heart issues.
- Source: India Times
- 1,322
- June 26, 2018
Researches vitamin
Call for HIMSS19 Global Conference Speaker Proposals

There will be a total of twenty-four education categories/topics, which includes five new topics namely consumerization of health, grand societal challenges, healthy aging and technology, population and public health management as well as supply chain management.
- Source: MobiHealthNews
- 650
- June 26, 2018
Company Insight digital health health IT HIMSS
FDA Anounces Restricted use of Keytruda & Tecentriq Against Bladder Cancer

Keytruda is now allowed only for the patients whose tumor expression levels of the biomarker PD-L1 meet a combined positive score of 10 or higher. Tecentriq can only be used where PD-L1 immune cells can cover only 5% or more of their tumor area.
- Source: FiercePharma
- 779
- June 26, 2018
bladder cancer Company Insights Merck Roche
Nanobiotix NBTXR3 in Late Phase Clinical Trial

NBTXR3 is composed of crystalline nanoparticles to amplify the efficacy of radiation therapy. The idea is to administer NBTXR3 as intra-tumoral injections before external beam radiation therapy, thereby increasing the antitumor effect, and thus preparing the patient for surgical resection.
- Source: FierceBiotech
- 612
- June 26, 2018
cancer Clinical Trials radiation therapy
AstraZeneca’s Durvalumab Receives Go-Ahead from DCGI to Market in India

Last Friday, pharma giant AstraZeneca announced that it had received the go-ahead from the Drug Controller General of India (DCGI) to import and market durvalumab (ImfinziTM) in India. The receipt of this permission paves the way for the launch of durvalumab (ImfinziTM) in India. Durvalumab which is a patented drug of Astra-Zeneca, received permission in India to provide treatment for patients with unresectable non-small cell lung cancer and metastatic urothelial carcinoma.
- Source: United News of India
- 2,553
- June 26, 2018
AstraZeneca cancer India New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.